Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

NCT ID: NCT02247362

Last Updated: 2015-04-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2016-03-31

Brief Summary

One dose of escalating strengths of an investigational influenza vaccine, VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine), will be evaluated for safety and immunogenicity in healthy adults 65 to 75 years of age in this placebo-controlled study.

Detailed Description

The purpose of this study is to evaluate, in a stepwise fashion, dose levels for an investigational quadrivalent influenza vaccine containing 2 influenza A strains and 2 influenza B strains. This is a multi-center, randomized, double-blind, placebo-controlled, dose escalating study in which up to 200 healthy adults age 65-75 years will be administered a single dose of either placebo or an investigational influenza vaccine (VAX2012Q, Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) at one of up to 3 dose levels. Fifty or up to 75 subjects will be enrolled in each dose level. Data for safety and immunogenicity will be collected for all dose levels.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Vaccine Dose Group 12 mcg

VAX2012Q, 12 mcg dose

Group Type: EXPERIMENTAL

VAX2012Q

Intervention Type: BIOLOGICAL

Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Vaccine Dose Group 20 mcg

VAX2012Q, 20 mcg dose

Group Type: EXPERIMENTAL

VAX2012Q

Intervention Type: BIOLOGICAL

Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Vaccine Dose Group 16 mcg

VAX2012Q; 16 mcg dose

Group Type: EXPERIMENTAL

VAX2012Q

Intervention Type: BIOLOGICAL

Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Vaccine Diluent

Vaccine Diluent, F147, as placebo control

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Vaccine Diluent

Interventions

VAX2012Q

Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Intervention Type: BIOLOGICAL

Placebo

Vaccine Diluent

Intervention Type: OTHER

Other Intervention Names

Quadrivalent Recombinant Hemagglutinin Influenza Vaccine; Vaccine Diluent

Eligibility Criteria

Inclusion Criteria

• Males and females aged 65-75 years of age at the time of vaccination in good health. Individuals that are stably treated for hypertension may be eligible.
• Able to provide informed consent
• Willing to receive the unlicensed vaccine
• Willing to provide multiple blood specimens
• Live in the community, independently or in an assisted living environment
• Based on the results of the Short Portable Mental Status Questionnaire be rated as normal or have no greater than mild severity dementia
• As defined by the Canadian Study of Health and Aging Clinical Frailty Scale be a Class 1 to 5

Exclusion Criteria

• Preceding the administration of study vaccine, has received or will receive 1) any licensed or investigational influenza vaccine product within 6 months, 2) any investigational drug or any investigational vaccine product other than influenza vaccine within the 30 days, 3) any licensed live vaccine other than influenza vaccine within 4 weeks, 4) any licensed inactivated vaccine other than influenza vaccine within 2 weeks
• Planned receipt before the Day 21 blood draw of 1) any licensed or investigational influenza vaccine product, 2) any investigational drug or any investigational vaccine product other than influenza vaccine, 3) any licensed live vaccine other than influenza vaccine, 4) any licensed inactivated vaccine other than influenza vaccine
• History of excessive alcohol use, drug abuse or significant psychiatric illness
• Has a chronic illness that is not medically stable, is receiving a concomitant therapy in which the medication dose has not been stable for at least 3 weeks prior to immunization or has any other condition that could interfere with the subject's participation in the study or interpretation of the study results
• Clinically significant abnormal liver function tests at screening
• Subjects with Grade 2 or higher abnormalities in total bilirubin at screening
• Subjects with any of the following laboratory abnormalities at screening: Creatinine >1.7mg/dL, Hemoglobin < 11g/dL for females; <12.5 g/dL for males, WBC <2500cell/mm3 or > 15,000cell/mm3 and Platelet Count <125,000cell/mm3
• Positive serology of HBSAg, HCV or HIV antibodies
• Having cancer or have received treatment for cancer within three years, excluding minor skin cancers, which are allowed unless located at the vaccination site. Persons with a history of cancer who are disease-free without treatment for three years or more are eligible.
• Persons with impaired immune responsiveness (of any cause), including Type 1 diabetes mellitus and auto immune disorders or any known or suspected autoimmune disease
• Persons with congenital immunodeficiency or history of acquired immunodeficiency, or immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months.
• Persons with a history of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component
• Persons with a history of Guillain-Barré Syndrome
• Receipt or donation of blood or blood products 8 weeks prior to vaccination or during the three week study period following vaccination
• Acute disease within 72 hours prior to vaccination.
• An oral temperature >100.4°F (38°C)
• Systolic blood pressure < 85 mm Hg and subjects whose hypertension is untreated or unstable with antihypertensive therapy or that have systolic BP ≥ 160 mm Hg or diastolic BP ≥ 100 mm Hg requiring medical intervention with more than one drug or more intensive therapy than previously used or indicated.
• Body Mass Index >40
• Disorders of coagulation
• Women less than 1 year post menopausal
• A clinical diagnosis of influenza within the previous 6 months
• Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study

• Minimum Eligible Age: 65 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

VaxInnate Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lynda Tussey, PHD

Role: STUDY_DIRECTOR

VaxInnate Corporation

Locations

Q-Pharm Pty Limited

Herston, Queensland, Australia

CMAX, a division of IDT Australia Limited

Adelaide, South Australia, Australia

Linear Clinical Research Limited

Nedlands, Western Australia, Australia

Countries

Australia

Other Identifiers

VAX2012Q-02

Identifier Type: -

Identifier Source: org_study_id